Quick Answer
Vir Biotechnology, Inc. reported Net Income Loss of -$437.99 million for the year ending 2025.
- Vir Biotechnology, Inc. showed an increase of +16.1% in Net Income Loss from 2024 to 2025.
- This data is from Vir Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Vir Biotechnology, Inc.'s Net Income Loss has declined by 527.0%.
- Historical annual values: Fiscal year 2025: -$437.99 million | Fiscal year 2024: -$521.96 million | Fiscal year 2023: -$615.06 million | Fiscal year 2022: $515.84 million | Fiscal year 2021: $528.58 million | Fiscal year 2020: -$298.67 million | Fiscal year 2019: -$174.68 million | Fiscal year 2018: -$115.88 million | Fiscal year 2017: -$69.85 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: